Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03620474|
Recruitment Status : Completed
First Posted : August 8, 2018
Last Update Posted : July 7, 2022
Kiminori Kimura, MD
Prism Pharma Co., Ltd.
National Center for Global Health and Medicine, Japan
Japan Agency for Medical Research and Development
Ohara Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Kiminori Kimura, MD, Komagome Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||July 13, 2021|
|Actual Study Completion Date :||February 28, 2022|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine. 2022 Jun;80:104069. doi: 10.1016/j.ebiom.2022.104069. Epub 2022 May 20.